313 related articles for article (PubMed ID: 17103444)
1. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
[TBL] [Abstract][Full Text] [Related]
5. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
8. Combination antifungal therapy for invasive aspergillosis.
Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis.
Maertens J
Int J Antimicrob Agents; 2006 Jun; 27(6):457-67. PubMed ID: 16701980
[TBL] [Abstract][Full Text] [Related]
10. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H; Waldenmaier D; Dahlke J; Ayuk FA; Wolschke C; Kröger N; Zander AR
Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
[TBL] [Abstract][Full Text] [Related]
13. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Herbrecht R; Maertens J; Baila L; Aoun M; Heinz W; Martino R; Schwartz S; Ullmann AJ; Meert L; Paesmans M; Marchetti O; Akan H; Ameye L; Shivaprakash M; Viscoli C
Bone Marrow Transplant; 2010 Jul; 45(7):1227-33. PubMed ID: 20062093
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of caspofungin therapy in children with invasive fungal infections.
Merlin E; Galambrun C; Ribaud P; Blanc T; Michel G; Auvrignon A; Stéphan JL
Pediatr Infect Dis J; 2006 Dec; 25(12):1186-8. PubMed ID: 17133169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]